Enhertu Demonstrates Promising Efficacy in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases

Enhertu Efficacy:
Enhertu (trastuzumab deruxtecan) has shown higher progression-free survival (PFS) and objective response rate (ORR) compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive unresectable and/or metastatic breast cancer, including those with stable brain metastases.

Brain Metastases Prevalence:
Approximately 22% to 50% of patients with HER2-positive metastatic breast cancer develop brain metastases, which are associated with a poorer prognosis and decreased quality of life.

Clinical Trial Results:
The DESTINY-Breast03 Phase III trial demonstrated that Enhertu had a median PFS of 15 months versus 3 months for T-DM1 in patients with stable brain metastases at baseline. Additionally, the confirmed ORR was 67.4% with Enhertu versus 20.5% with T-DM1 in this subgroup.

Intracranial Efficacy:
Enhertu has shown promising intracranial efficacy in patients with both stable and active brain metastases, with an intracranial ORR of 45.2% in patients with stable BMs and 45.5% in patients with active BMs.

Treatment Need:
There is a significant need for additional systemic treatment options for patients with HER2-positive metastatic breast cancer and brain metastases, as current treatments often have limited ability to cross the blood-brain barrier and control intracranial lesions effectively.